recast-jats-build1d2b230b09jitcJ Immunother CancerjitcJournal for ImmunoTherapy of CancerJ Immunother CancerJ Immunother Cancer2051-1426BMJ Publishing Group Ltdjitc-2019-000379corr110.1136/jitc-2019-000379corr132345626/jitc/8/1/e000379corr1.atomCorrectionOpen accessSpecial collectionsOpen accessCorrection: T lymphocyte-targeted immune checkpoint modulation in glioma 4202026420202012201920122019284202081e000379corr1© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.2020http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.special-featureunlocked

Kelly WJ, Giles AJ, Gilbert M. T lymphocyte-targeted immune checkpoint modulation in glioma. J Immunotherapy Cancer 2020;8:e000379. doi: 10.1136/jitc-2019-000379

Since the online publication of this article, the corresponding author has provided a new email address; William Kelly william.kelly@nih.gov.